HIV Vaccine Research: Science & Development

Why HIV has challenged vaccine scientists for decades, what past trials taught the field, and how today’s investigational strategies aim to induce broadly neutralizing antibodies.

No approved HIV vaccineInvestigational candidates onlyPublished trial evidence

This website provides general educational information and does not replace professional medical advice, diagnosis, or treatment. Medical guidance and research findings may change. Consult qualified healthcare professionals for individual health concerns.

Why HIV Vaccine Research Matters

More than four decades after HIV was identified, the world has powerful tools to prevent and treat it. Antiretroviral therapy allows people with HIV to live long, healthy lives and prevents sexual transmission when viral load is undetectable. Pre-exposure prophylaxis protects people who do not have HIV. Yet UNAIDS estimates that about 1.3 million people acquired HIV in 2024. Many people face barriers to testing, clinics, medication and consistent follow-up.

A safe and effective vaccine could complement these tools by providing protection that does not depend on regular dosing. That is why HIV vaccine research continues, even after setbacks.

Current status

No HIV vaccine has been approved for general use. Every candidate described on this page is investigational and is studied only within regulated clinical trials.

The Scientific Challenges of HIV

Most successful vaccines imitate the immunity that people develop after recovering from a natural infection. HIV offers no such model: the immune system almost never clears HIV on its own. Several features make it an exceptionally difficult target:

  • Rapid mutation. HIV’s replication process is error-prone, so the virus changes constantly, even within a single person.
  • Integration and latency. Soon after infection, HIV inserts its genetic material into the DNA of host cells and can lie dormant in a long-lived reservoir that the immune system cannot see.
  • Attack on the immune system itself. HIV targets CD4 helper T cells, which are central to coordinating immune responses.
  • A shielded surface protein. The envelope protein (Env), the main target for antibodies, is covered with a dense layer of sugar molecules—a “glycan shield”—and changes shape in ways that hide vulnerable sites.

Understanding HIV Genetic Diversity

HIV is classified into types (HIV-1 and the less common HIV-2), groups and subtypes, also called clades. Most infections worldwide involve HIV-1 group M, which includes subtypes such as A, B, C and D, as well as recombinant forms that combine genetic material from different subtypes. Subtype C accounts for a large share of infections worldwide, especially in southern Africa, while subtype B predominates in North America and Western Europe.

Genetic variation between subtypes, and even within a single subtype, is far greater than the variation seen in influenza viruses. A vaccine would need to protect against the many strains circulating where it is used.

The Role of the Immune System

Researchers are exploring several kinds of immune responses that might prevent or control HIV:

  • Neutralizing antibodies that bind to the virus and prevent it from entering cells.
  • Non-neutralizing antibody functions, in which antibodies help other immune cells destroy infected cells.
  • T-cell responses, particularly CD8+ T cells that can kill infected cells and potentially limit early infection.

Most experts believe an effective preventive vaccine will need to induce broadly neutralizing antibodies, likely supported by T-cell immunity.

Vaccine Research Approaches

The history of HIV vaccine efficacy trials has shaped today’s strategies:

Selected HIV vaccine efficacy trials and published outcomes. None led to an approved vaccine.
StudyApproachPublished outcome
VaxGen trials (early 2000s)Envelope protein (gp120) to induce antibodiesNo protection observed
Step study, HVTN 502 (2007)Adenovirus-vector vaccine to induce T-cell responsesStopped early; no protection observed
RV144, Thailand (2009)Canarypox-vector prime with protein boostModest, short-lived reduction in risk (estimated efficacy 31.2%); not sufficient for licensure
HVTN 702 “Uhambo,” South Africa (stopped 2020)Regimen adapted from RV144 for subtype CNo protection observed
HVTN 705 “Imbokodo” (2021) and HVTN 706 “Mosaico” (2023)“Mosaic” antigens designed to cover diverse strainsDid not provide sufficient protection; trials concluded

Today, much of the field focuses on rational, structure-based vaccine design, stabilized versions of the Env protein (“native-like trimers”), and new delivery platforms including mRNA.

Broadly Neutralizing Antibodies

A minority of people living with HIV eventually develop broadly neutralizing antibodies (bnAbs), which can neutralize a wide range of HIV strains by binding to relatively stable sites on the Env protein. These antibodies usually take years to develop and require many rounds of maturation.

The Antibody Mediated Prevention (AMP) studies tested whether infusions of one bnAb, VRC01, could prevent HIV. Published in 2021, the results showed that VRC01 did not reduce overall HIV acquisition, but it appeared to protect against strains that were highly sensitive to the antibody. This was important proof that antibodies of this kind can prevent infection if present at sufficient levels.

A leading vaccine strategy, known as germline targeting, aims to activate the rare B cells capable of becoming bnAb producers and then guide them, step by step, with a sequence of different immunogens. In the IAVI G001 Phase 1 trial, published in Science in 2022, an engineered immunogen activated the intended precursor B cells in nearly all recipients who received it. Follow-on studies, including IAVI G004, which began vaccinating participants in South Africa in December 2025, and the BRILLIANT 011 first-in-human trial launched in Cape Town in January 2026, are early-phase studies of safety and immune responses. They are not designed to show protection.

bnAb
Broadly neutralizing antibody
An antibody that can block infection by many different strains of a virus by targeting conserved regions of the virus’s surface.

Preclinical Research

Before testing in people, candidates are studied in laboratory systems and animal models. Researchers use protein structure imaging, computational design and specially engineered mice that carry human antibody genes. Non-human primate studies often use SHIV, a laboratory virus combining parts of SIV and HIV. Animal results help select candidates, but they do not reliably predict how people will respond.

Clinical Trial Development

HIV vaccine candidates progress through the same phases as other vaccines, described on our Clinical Trial Education page. Early trials are small and focus on safety and immune responses. Only candidates that show convincing immune responses and acceptable safety would advance to large efficacy trials. Trial participants receive HIV prevention counseling and access to prevention tools such as condoms and referrals for PrEP, so the trial does not leave them less protected than they would otherwise be.

Understanding Research Results

Headlines about HIV vaccines can be misleading. When reading about results, it helps to ask:

  • What phase was the trial, and how many people took part?
  • Did it measure protection from HIV, or only immune responses in the blood?
  • Has the result been peer reviewed and published?
  • Does “promising” mean the candidate prevented infection, or that it produced a hoped-for immune response?

An immune response in a Phase 1 trial is an encouraging step, but it is not evidence that a vaccine will prevent HIV.

Challenges and Future Directions

Major open questions remain: how to reliably induce bnAbs in most people, how long protection could last, how to cover the virus’s diversity, and how to make any eventual vaccine affordable and available where it is most needed. Researchers are also studying long-acting injectable antibodies and combinations of approaches. Progress depends on volunteers, sustained funding, international collaboration and meaningful community engagement.

Frequently Asked Questions

Is there an approved HIV vaccine?

No. As of this page’s most recent update, no HIV vaccine has been approved by the US Food and Drug Administration or any other major regulator for preventing HIV. All HIV vaccine candidates are investigational and are being studied only within clinical trials.

Can an HIV vaccine candidate give someone HIV?

The candidates tested in modern trials do not contain live, replicating HIV or the virus’s complete genetic material, so they cannot cause HIV infection. Some candidates can, however, cause the body to make antibodies that make a standard HIV antibody test show a reactive result. This is called vaccine-induced seropositivity, and trial teams provide specialized testing to distinguish it from true infection.

If PrEP and treatment work so well, why is a vaccine still needed?

PrEP and treatment are highly effective, but they depend on regular access to health services, testing and medication. Global efforts have not reached everyone who could benefit. A safe, effective and durable vaccine could add protection that does not rely on daily or periodic dosing, which is why researchers continue to pursue one.

What does it mean when an HIV vaccine trial is stopped early?

Trials have independent monitoring boards that review results as they accumulate. A trial may be stopped early if it becomes clear the candidate is unlikely to show meaningful protection (often called futility), or because of safety concerns. Stopping for futility is disappointing, but it protects participants and redirects resources to more promising approaches.

How can I learn about HIV vaccine trials?

THE VARG does not list, recruit for or endorse specific studies. Public trial registries maintained by national health authorities, and conversations with qualified clinicians, are appropriate places to find information about research participation.